The biotech is developing an RNA-based therapy for what it describes as a root cause of the pregnancy-related complication, which affects millions of women.

A pair of newly FDA-cleared blood tests from Thermo Fisher Scientific could be a major boon in the early detection and treatment of preeclampsia, a pregnancy complication that can endanger both the mother and fetus—and one that’s risen in prevalence in the U.S. in recent years.

In honor of Mother's Day in the United States, we're spotlighting game-changing maternal health technologies.